Results 131 to 140 of about 325,802 (246)

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms. [PDF]

Transl Oncol
De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Ramos A, Moreno-Castaño AB, Arellano-Rodrigo E, Escolar G, Carreras E, Álvarez-Larrán A, Diaz-Ricart M.   +9 more
europepmc   +1 more source

Complement-activating lectin, RaRF.

Nippon Saikingaku Zasshi, 1999
openaire   +3 more sources

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Mesenchymal stem cell exosomes alleviate osteoarthritis by inhibiting complement activation via a CD59-dependent pathway. [PDF]

Arthritis Res Ther
Jiang Y, Ng CY, Seow DSK, Loh JT, Wong RCW, Hui JHP, Toh WS.   +6 more
europepmc   +1 more source

Reduced Muscular Carnosine in Proximal Myotonic Myopathy—A Pilot 1H‐MRS Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Myotonic dystrophy type 2 (proximal myotonic myopathy, PROMM) is a progressive multisystem disorder with muscular symptoms (proximal weakness, pain, myotonia) and systemic manifestations such as diabetes mellitus, cataracts, and cardiac arrhythmias.
Alexander Gussew, Maryam Kargaran, Maik Rothe, Andreas Deistung, Dietrich Stoevesandt, Walter A. Wohlgemuth, David Strube, Thomas Kendzierski, Anna Katharina Kölsch, Maurits Gerhard Abraham Heuschen, Markus Otto, Alexander Mensch   +11 more
wiley   +1 more source

The temporal gene expression landscape of rhabdomyolysis-induced acute kidney injury reveals the timing of complement activation. [PDF]

Commun Biol
Grunenwald A, Boudhabhay I, Revel M, Poillerat V, Voilin E, Majdi A, Chaibi K, Gaudry S, Woodruff TM, Crambert G, Guihaire J, Zaidan M, Oniszczuk J, Frimat M, Gnemmi V, Aletti M, Nielly H, Gilardin L, Roumenina LT.   +18 more
europepmc   +1 more source

Complement activity and vitamin C [PDF]

Biochemical Journal, 1943
E. Kodicek, B. Traub
openaire   +2 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Exploring the intersection of atherosclerosis and Alzheimer's disease: the role of inflammation and complement activation. [PDF]

Inflamm Res
Vataja E, Ratti G, Safa A, Pagano M, Ferrante L, Meri S, Haapasalo K.   +6 more
europepmc   +1 more source